Ocular toxicities of fibroblast growth factor receptor inhibitors: A review Review
| Authors: | Hsu, J.; Francis, J. H.; Ahmad, S. |
| Review Title: | Ocular toxicities of fibroblast growth factor receptor inhibitors: A review |
| Abstract: | Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer drugs with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in clinical trials, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye has been reported, but the ocular surface and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy, respectively. Corneal thinning and melt is a rare but serious and potentially vision-threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases. © 2023 Elsevier Inc. |
| Keywords: | protein expression; treatment outcome; treatment response; antibiotic agent; unclassified drug; review; dose response; nonhuman; treatment duration; antineoplastic agents; antineoplastic agent; protein function; metabolism; protein kinase inhibitor; steroid; fibroblast growth factor receptor 3; protein tyrosine kinase inhibitor; nail disease; protein kinase inhibitors; hair disease; cataract; retina detachment; retinopathy; eye disease; periorbital edema; diplopia; dry eye; treatment withdrawal; eye toxicity; fibroblast growth factor receptor 1; fibroblast growth factor receptor 2; blurred vision; ophthalmoscopy; keratitis; bacterial superinfection; trichiasis; onycholysis; eye diseases; conjunctivitis; adverse events; subretinal fluid; macular degeneration; retina disease; fibroblast growth factor receptor; cornea disease; fibroblast growth factor receptor 4; cornea ulcer; receptors, fibroblast growth factor; ocular pruritus; eye discharge; lacrimation disorder; blepharitis; azd 4547; eyelid disease; humans; human; ocular toxicity; cornea erosion; erdafitinib; fpa 144; gsk 3052230; infigratinib; lens disease; central serous retinopathy; pemigatinib; rogaratinib; bemarituzumab; derazantinib; futibatinib; zoligratinib; fgfr inhibitor; aprutumab ixadotin; artificial tear; fibroblast growth factor receptor 5; fp 1039; jnj 4275693; ly 2874455; tasurgratinib; limbal stem cell deficiency; meibomian gland dysfunction; vitreous body detachment |
| Journal Title: | Survey of Ophthalmology |
| Volume: | 69 |
| Issue: | 1 |
| ISSN: | 0039-6257 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-01-01 |
| Start Page: | 34 |
| End Page: | 41 |
| Language: | English |
| DOI: | 10.1016/j.survophthal.2023.09.007 |
| PUBMED: | 37777119 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
